The gene therapy developer appears to be struggling to find a safe and effective dose of its experimental Duchenne muscular dystrophy treatment.
News & Analysis: Solid Biosciences Inc.
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.
The company announced disappointing early results for a muscular dystrophy gene therapy.
These gene therapy stocks have generated huge returns so far this year. But can they keep up their winning ways?
Is continued success in the cards for these biotech stocks?
Find out why healthcare made a big leap in today's market action.
A bad reaction to its muscular dystrophy candidate could spell the end for a biotech that's just getting started.